|
Oct 24
|
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
|
|
Jul 23
|
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
|
|
Jun 25
|
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
|
|
Jun 24
|
The past three years for AxoGen (NASDAQ:AXGN) investors has not been profitable
|
|
Jun 24
|
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
|
|
May 16
|
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
|
|
May 14
|
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
|
|
May 6
|
AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript
|
|
May 3
|
AxoGen First Quarter 2024 Earnings: Misses Expectations
|
|
May 3
|
Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges
|
|
May 2
|
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 2
|
Axogen, Inc Reports First Quarter 2024 Financial Results
|
|
May 1
|
AxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the company
|
|
Apr 29
|
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
|
|
Apr 16
|
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
|
|
Apr 4
|
Analysts Expect Breakeven For AxoGen, Inc. (NASDAQ:AXGN) Before Long
|
|
Mar 9
|
Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)
|
|
Mar 8
|
US$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These Results
|
|
Mar 6
|
AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript
|
|
Mar 6
|
AxoGen Full Year 2023 Earnings: Beats Expectations
|